Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,201–1,300 of 4,275
Lung cellular senescence is independent of aging in a mouse model of COPD/emphysema
Rashid, K., Sundar, I. K., Gerloff, J., Li, D., & Rahman, I. (2018) · Scientific Reports · doi:10.1038/s41598-018-27209-3 · Cited by 58
p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells
Janelle, V., Neault, M., Lebel, M., Sousa, D. M. D., Boulet, S., Durrieu, L., Carli, C., Muzac, C., Lemieux, S., Labrecque, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698565 · Cited by 67
The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy
Cao, L., Li, K., Li, Q., Tong, Q., Wang, Y., & Huang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02475-8 · Cited by 90
“Numerous studies demonstrate SASP’s adaptability to diverse cell types [28, 171].”
Shang, D., Sun, D., Shi, C., Xu, J. L., Shen, M., Hu, X., Liu, H., & Tu, Z. (2020) · Aging Cell · doi:10.1111/acel.13145 · Cited by 65
“The senescence-associated secretory phenotype (SASP) is one of the most important features of senescent cells (Coppe et al., 2008; Kuilman et al., 2008), and several groups have intensively studied the cell-autonomous mechanisms for SASP regulation using different cell models and stimuli (Freund,…”
BackgroundSenolytics: A Translational Bridge Between Cellular Senescence and Organismal Aging
Thoppil, H., & Riabowol, K. T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00367 · Cited by 64
Chromosome organisation during ageing and senescence
Chandra, T., & Kirschner, K. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.03.020 · Cited by 62
Polettini, J., Dutta, E. H., Behnia, F., Saade, G. R., Torloni, M. R., & Menon, R. (2015) · Placenta · doi:10.1016/j.placenta.2015.05.003 · Cited by 63
“Aging is an irreversible process, unlike apoptosis (programmed cell death), and can elicit an inflammatory response [7].”
Backgroundp53 Isoforms in Cellular Senescence- and Ageing-Associated Biological and Physiological Functions
Fujita, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236023 · Cited by 56
Picca, A., Guerra, F., Calvani, R., Coelho‐Júnior, H. J., Landi, F., Bernabei, R., Romanò, R., Bucci, C., & Marzetti, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.601740 · Cited by 60
Cellular senescence: a double‐edged sword in the fight against cancer
Ohtani, N., Takahashi, A., Mann, D. J., & Hara, E. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01493.x · Cited by 57
Senescence and tumor suppression
Hinds, P., & Pietruska, J. (2017) · F1000Research · doi:10.12688/f1000research.11671.1 · Cited by 57
Wang, J., Zheng, X., Qin, Z., Wei, L., Lu, Y., Qiu, P., Gao, Y., Zhang, X., Zhang, X., Li, Z., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006853 · Cited by 61
“They express a large number of secreted proteins, which is known as SASP (15).”
BackgroundInfluentialDinh, N. T. M., Nguyen, T. M., Park, M. K., & Lee, C. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020717 · Cited by 63
Probing the depths of cellular senescence
Baker, D. J., & Sedivy, J. M. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201305155 · Cited by 56
“For example, one could ask whether the proteolytically cleaved products can serve as input material to promote the senescenceassociated secretory phenotype (SASP; Coppé et al., 2008).”
BackgroundInflammatory Mechanisms in Heart Failure with Preserved Ejection Fraction
Daou, D., Gillette, T. G., & Hill, J. A. (2023) · Physiology · doi:10.1152/physiol.00004.2023 · Cited by 95
Defective NCOA4-dependent ferroptosis in senescent fibroblasts retards diabetic wound healing
Wei, X., Liu, M., Zheng, Z., Yu, S., Huang, L., Ma, J., Gao, Y., Peng, Y., Chen, L., Tan, R., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01437-7 · Cited by 68
“This research was authorized by the Ethics Committee of the Nanfang Hospital of Southern Medical University.”
The Mechanisms and Efficacy of Photobiomodulation Therapy for Arthritis: A Comprehensive Review
Zhang, R., & Qu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814293 · Cited by 75
“Notably, fibrocytes and mesenchymal stem cells have the potential to differentiate into senescence-related secretory phenotypes, producing inflammatory cytokines, chemokines, and growth factors [129,130].”
Hubackova, S., Novakova, Z., Krejcikova, K., Kosar, M., Dobrovolna, J., Duskova, P., Hanzlikova, H., Vancurova, M., Barath, P., Bartek, J., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.15.12521 · Cited by 56
The infrapatellar fat pad in inflammaging, knee joint health, and osteoarthritis
Wang, M. G., Seale, P., & Furman, D. (2024) · npj Aging · doi:10.1038/s41514-024-00159-z · Cited by 78
Cerchietti, L. C. A. (2024) · Blood · doi:10.1182/blood.2023021002 · Cited by 68
MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine
Smith, B., Agarwal, P., & Bhowmick, N. A. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-16-0525 · Cited by 56
Alveolar type 2 epithelial cell senescence and radiation-induced pulmonary fibrosis
Zhou, S., Zhu, J., Zhou, P., & Gu, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.999600 · Cited by 61
“Furthermore, they serve as a new mechanism for the cellular senescence effect (Coppé et al., 2008; Freund et al., 2010; Aird et al., 2016; Yin et al., 2021).”
BackgroundDNA Damage Response in Hematopoietic Stem Cell Ageing
Li, T., Zhou, Z.-W., Ju, Z., & Wang, Z.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.04.002 · Cited by 55
Ma, K., Xu, Q., Wang, S., Zhang, W., Liu, M., Liang, S., Zhu, H., & Xu, N. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.045 · Cited by 62
Mavrogonatou, E., Konstantinou, A., & Kletsas, D. (2018) · Biogerontology · doi:10.1007/s10522-018-9753-9 · Cited by 63
Shang, J., Yao, Y., Fan, X., Shangguan, L., Li, J., Liu, H., & Zhou, Y. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.005 · Cited by 60
p16INK4a Exerts an Anti-Inflammatory Effect through Accelerated IRAK1 Degradation in Macrophages
Murakami, Y., Mizoguchi, F., Saito, T., Miyasaka, N., & Kohsaka, H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103156 · Cited by 56
Probiotic bacteria as modulators of cellular senescence: emerging concepts and opportunities
Sharma, R., & Padwad, Y. S. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1697148 · Cited by 56
“It is also pertinent to note here that senescent cells are not only characterized by the loss of proliferative capacity but also show several unique-associated features such as high metabolic activity,(22) activation of nutrient-sensing pathways such as mammalian target of rapamycin (mTOR),(23) and the development of…”
BackgroundKlein, D., Schmetter, A., Imsak, R., Wirsdörfer, F., Unger, K., Jastrow, H., Stuschke, M., & Jendrossek, V. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6183 · Cited by 57
“The SASP includes inflammatory cytokines, growth factors, and proteases with potential immunomodulatory function, and some of the SASP proteins even have a suspected tumor-promoting effect (8, 14, 15, 43).”
Targeting normal and cancer senescent cells as a strategy of senotherapy
Sikora, E., Bielak-Zmijewska, A., & Mosieniak, G. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100941 · Cited by 56
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Liver regeneration in aged mice: new insights
Pibiri, M. (2018) · Aging · doi:10.18632/aging.101524 · Cited by 60
“proinflammatory proteins IL-6, IL-8, IL-1, granulocyte macrophage colony stimulating factor (GM-CSF), growth regulated oncogene (GRO)α, monocyte chemotactic protein (MCP)-2, MCP-3, MMP-1, MMP-3, and many of the Insulin-like growth factor (IGF)-binding proteins) [206,226-228].”
BackgroundInfluentialCellular senescence as a possible link between prostate diseases of the ageing male
Fiard, G., Stavrinides, V., Chambers, E. S., Heavey, S., Freeman, A., Ball, R., Akbar, A. N., & Emberton, M. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00496-8 · Cited by 62
Carpenter, V. J., Saleh, T., Lee, S. M., Murray, G. F., Reed, J. C., Souers, A. J., Faber, A. C., Harada, H., & Gewirtz, D. A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114765 · Cited by 63
Acute ischemic stroke triggers a cellular senescence-associated secretory phenotype
Torres-Querol, C., Torres, P., Vidal, N., Portero‐Otín, M., Arqué, G., & Purroy, F. F. (2021) · Scientific Reports · doi:10.1038/s41598-021-95344-5 · Cited by 64
Chakrabarty, A., Chakraborty, S., Bhattacharya, R., & Chowdhury, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.674354 · Cited by 62
Terao, R., Lee, T. J., Colasanti, J. J., Pfeifer, C. W., Lin, J. B., Santeford, A. C., Hase, K., Yamaguchi, S., Du, D., Sohn, B. S., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114102 · Cited by 69
p53 in Bronchial Club Cells Facilitates Chronic Lung Inflammation by Promoting Senescence
Sagiv, A., Bar-Shai, A., Levi, N., Hatzav, M., Zada, L., Ovadya, Y., Roitman, L., Manella, G., Regev, O., Majewska, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.009 · Cited by 55
Effenberger, T., von der Heyde, J., Bartsch, K., Garbers, C., Schulze‐Osthoff, K., Chalaris, A., Murphy, G., Rose‐John, S., & Rabe, B. (2014) · The FASEB Journal · doi:10.1096/fj.14-254565 · Cited by 54
“ADAM17 plays a crucial role in various inflammatory settings by proteolytic shedding of immunologically relevant molecules, such as TNF- and L-selectin (16), which have also frequently been found as integral SASP components (3, 9).”
BackgroundMethodInfluentialRehman, A., Ali, S., Lone, M. A., Atif, M., Hassona, Y. M., Prime, S. S., Pitiyage, G. N., James, E. L., & Parkinson, E. K. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12370 · Cited by 60
“Specifically, the OSMF senescent population appears to be enriched for MMPs, whereas the rest of the population is not and may therefore explain why, overall, the OSMF population might have an increased propensity for fibrosis owing to a lower MMP/TIMP balance, whereas the senescent fraction could locally ameliorate f…”
BackgroundResultInfluentialSenescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer
Banerjee, P., Kotla, S., Velatooru, L. R., Abe, R. J., Olmsted‐Davis, E. A., Cooke, J. P., Schadler, K., Deswal, A. M., Herrmann, J., Lin, S. H., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.763930 · Cited by 57
“These findings suggest that SASP might be permanently locked in an irreversible stage by unknown mechanisms that uncoupling senescence-associated cell cycle arrest from the SASP (24).”
BackgroundResultInfluentialPerrigue, P. M., Silva, M. E., Warden, C. D., Feng, N. L., Reid, M. A., Mota, D. J., Joseph, L. P., Tian, Y. I., Glackin, C. A., Gutova, M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0268 · Cited by 55
“This cytokine secretory profile is similar to that reported for senescent fibroblasts and other cells (11, 51).”
BackgroundDańczak‐Pazdrowska, A., Gornowicz‐Porowska, J., Polańska, A., Krajka‐Kuźniak, V., Stawny, M., Gostyńska, A., Rubiś, B., Noureddine, S. A., Ashiqueali, S., Schneider, A., et al. (2023) · Aging Cell · doi:10.1111/acel.13845 · Cited by 71
Menon, R. (2022) · Immunological Reviews · doi:10.1111/imr.13075 · Cited by 68
Corpet, A., & Stucki, M. (2014) · Chromosoma · doi:10.1007/s00412-014-0469-6 · Cited by 63
“This feature—referred to as the senescence-associated secretory phenotype (SASP) (Coppe et al. 2008)—participates in the reinforcement of the arrested state (Acosta et al.”
BackgroundShang, D., Hong, Y., Xie, W., Tu, Z., & Xu, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00929 · Cited by 54
“In addition, senescent cells typically show a senescenceassociated secretory phenotype (SASP) and secrete various pro-inflammatory cytokines (15, 16).”
BackgroundCytoplasmic chromatin fragments-from mechanisms to therapeutic potential.
Miller, K. N., Dasgupta, N., Liu, T., Adams, P. D., & Vizioli, M. G. (2021) · eLife · doi:10.7554/elife.63728 · Cited by 55
“While the biological significance of the SASP has been intensively studied (Acosta et al., 2008; Coppé et al., 2010; Coppé et al., 2008; Krtolica et al., 2001; Kuilman et al., 2008), the mechanisms that initiate and sustain the SASP are poorly understood.”
BackgroundIonizing Radiation-Induced Brain Cell Aging and the Potential Underlying Molecular Mechanisms
Wang, Q., Yin, G., Huang, J., Xi, S.-J., Qian, F., Lee, R.-X., Peng, X., & Tang, F. R. (2021) · Cells · doi:10.3390/cells10123570 · Cited by 62
Rudnick, J. A., Arendt, L. M., Klebba, I., Hinds, J. W., Iyer, V., Gupta, P. B., Naber, S. P., & Kuperwasser, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024605 · Cited by 54
“The basal level of IL-6 varied widely among patient derived breast fibroblasts, and also increased with passage number, consistent with previous reports using primary fibroblasts”
Lipopolysaccharides and Cellular Senescence: Involvement in Atherosclerosis
Suzuki, K., Susaki, E. A., & Nagaoka, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911148 · Cited by 56
“In contrast, senescent cells were also found to secrete various inflammatory factors, a state referred to as senescence-associated secretory phenotype (SASP) [15,16].”
BackgroundEl‐Far, A. H., Darwish, N. H. E., & Mousa, S. A. (2020) · Integrative Cancer Therapies · doi:10.1177/1534735419901160 · Cited by 60
Helbling-Leclerc, A., Garcin, C., & Rosselli, F. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00764-5 · Cited by 61
“● Secretory phenotype Senescent cells secrete many factors, such as cytokines (IL-1α, IL-6, IL-13), chemokines (IL-8, CCL2), inflammatory molecules (TGF-β, IFN-γ), proteinases (MMP-14, MMP-7, MMP-3) and growth factors, which regulate several biological process [61].”
BackgroundRegulation of Senescence in Cancer and Aging
Kong, Y., Cui, H., Ramkumar, C., & Zhang, H. (2011) · Journal of Aging Research · doi:10.4061/2011/963172 · Cited by 68
“[16] J.”
Rivera, J., & José, E. S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01011 · Cited by 58
“Cell senescence defines an irreversible cell-cycle arrest accompanied by phenotypic changes including resistance to apoptosis and production of senescent-associated secreted phenotype (Coppe et al., 2008).”
BackgroundMutant p53 in cell-cell interactions
Pilley, S., Rodriguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 53
“The consequences of SASP induction can be both tumorpromoting and tumor-limiting (Coppé et al. 2010), and the promalignant activities of SASP have been shown to be reduced by p53 (Coppé et al. 2008).”
BackgroundScarabino, D., Peconi, M., Broggio, E., Gambina, G., Maggi, E., Armeli, F., Mantuano, E., Morello, M., Corbo, R. M., & Businaro, R. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110945 · Cited by 67
DNA damage responses in ageing
da Silva, P. F. L., & Schumacher, B. (2019) · Open Biology · doi:10.1098/rsob.190168 · Cited by 55
“Cellular senescence might have evolved as a tumour suppression mechanism with clearly beneficial effects early on; however, as senescent cell frequencies increase with age [105,106], the deleterious effects, mainly of the SASP, start to outweigh the initial, ‘selectedthrough-evolution’, beneficial effects.”
BackgroundInfluentialMicroRNAs are critical regulators of senescence and aging in mesenchymal stem cells
Potter, M. L., Hill, W., Isales, C. M., Hamrick, M. W., & Fulzele, S. (2020) · Bone · doi:10.1016/j.bone.2020.115679 · Cited by 61
“Senescent cells are also well characterized by their altered secretome consisting of proinflammatory cytokines, chemokines, and extracellular matrix proteins, collectively known as the senescence-associated secretory phenotype (SASP) (11, 12).”
BackgroundPIM‐1 modulates cellular senescence and links IL‐6 signaling to heterochromatin formation
Jin, B., Wang, Y., Wu, C. L., Liu, K. Y., Chen, H., & Mao, Z. B. (2014) · Aging Cell · doi:10.1111/acel.12249 · Cited by 54
“Previous reports have shown that PIM-1 gene expression is induced by a large set of cytokines (Bachmann & Moroy, 2005), and many cytokine genes, including IL-6 and IL-8, are activated during senescence (Coppe et al., 2008).”
BackgroundFunctional Interaction between Melatonin Signaling and Noncoding RNAs
Su, S., Reiter, R. J., Hsiao, H., Chung, W., & Yang, S. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.008 · Cited by 55
Błoniarz, D., Adamczyk‐Grochala, J., Lewińska, A., & Wnuk, M. (2021) · Aging · doi:10.18632/aging.203203 · Cited by 61
“We suggest that DNMT2/TRDMT1 gene knockout in selected experimental settings may potentiate some adverse effects associated with chemotherapy-induced senescence. www.aging-us.com 15834 AGING elimination of cancer-associated senescent cells both cancer cells and normal cells by senolytic drugs and the attenuation of SA…”
BackgroundInfluentialInflammation, Immune Senescence, and Dysregulated Immune Regulation in the Elderly
Shive, C. L., & Pandiyan, P. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.840827 · Cited by 63
“Continuous exposure to immune stressors results in senescent cells that further contribute to ongoing inflammation by secretion of SASP.”
BackgroundChemotherapeutic Resistance: Surviving Stressful Situations
Gilbert, L. A., & Hemann, M. T. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0277 · Cited by 54
Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment
Koutroumpakis, E., Deswal, A. M., Yusuf, S. W., Abe, J., Nead, K. T., Potter, A. S., Liao, Z. X., Lin, S. H., & Palaskas, N. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01238-8 · Cited by 61
Miller, R. A., Betteken, M. I., Guo, X., Altier, C., Duhamel, G. E., & Wiedmann, M. (2018) · mBio · doi:10.1128/mbio.00467-18 · Cited by 55
“…is an anti-inflammatory cell death pathway (41), senescence is associated with the release of proinflammatory cytokines, known as the senescence-associated secretory phenotype (SASP), which serves as an innate signaling mechanism to recruit inflammatory cells to the site of senescent cells (42, 43).”
Periodontal Disease and Senescent Cells: New Players for an Old Oral Health Problem?
Aquino-Martínez, R., Khosla, S., Farr, J. N., & Monroe, D. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207441 · Cited by 66
“Although the impact on other cells is triggered by the combined effect of multiple soluble signals, specific factors and signaling pathways have a relevant role in this process [46,47].”
BackgroundEnergetic interventions for healthspan and resiliency with aging
Huffman, D. M., Schafer, M. J., & LeBrasseur, N. K. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.05.012 · Cited by 54
GDF‐15 is associated with sarcopenia and frailty in acutely admitted older medical patients
Kamper, R. S., Nygaard, H. H., Praeger‐Jahnsen, L., Ekmann, A., Ditlev, S. B., Schultz, M., Hansen, S. K., Hansen, P., Pressel, E., & Suetta, C. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13513 · Cited by 63
“1,2 Senescent cells are associated with a distinctive secretory phenotype termed the senescence-associated secretory phenotype (SASP), consisting of a panel of in fl ammatory proteins, 32 and a large production of mitochondrial derived reactive oxygen species (ROS).”
BackgroundZhou, B., Fang, L., Dong, Y., Yang, J., Chen, X., Zhang, N., Zhu, Y., & Huang, T. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03660-5 · Cited by 58
Inflammation and Pyroptosis Mediate Muscle Expansion in an Interleukin-1β (IL-1β)-dependent Manner
Haldar, S., Dru, C. J., Choudhury, D., Mishra, R., Fernandez, A., Biondi, S., Liu, Z., Shimada, K., Arditi, M., & Bhowmick, N. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.617886 · Cited by 54
“Senescenceassociated secretome expression may explain some of the observed muscular expansion (26).”
BackgroundChou, L.-Y., Ho, C.-T., & Hung, S. (2022) · Cells · doi:10.3390/cells11203324 · Cited by 66
“As MSCs age, these cells are able to exert their effects in the surrounding environment and modulate their niche as a result of a unique secretome profile, which is termed the “senescence-associated secretory phenotype” or SASP [9,10].”
BackgroundRestored immune cell functions upon clearance of senescence in the irradiated splenic environment
Palacio, L., Goyer, M., Maggiorani, D., Espinosa, A., Villeneuve, N., Bourbonnais, S., Moquin‐Beaudry, G., Le, O., Demaria, M., Davalos, A. R., et al. (2019) · Aging Cell · doi:10.1111/acel.12971 · Cited by 54
Translational Control during Cellular Senescence
Payea, M. J., Anerillas, C., Tharakan, R., & Gorospe, M. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00512-20 · Cited by 54
“during senescence (18) and inhibition of the mTORC1 pathway suppresses the SASP”
BackgroundDNA Damage Response and Metabolic Reprogramming in Health and Disease
Chatzidoukaki, O., Goulielmaki, E., Schumacher, B., & Garinis, G. A. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.06.018 · Cited by 62
Sundar, I. K., Rashid, K., Gerloff, J., Li, D., & Rahman, I. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0390oc · Cited by 53
Sharma, R., & Padwad, Y. S. (2020) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.02.004 · Cited by 56
Dynamic 3D genome reorganization during senescence: defining cell states through chromatin
Shaban, H. A., & Gasser, S. M. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01197-y · Cited by 61
“Besides the down-regulation of cell cycle genes, senescent cells are programmed to upregulate several chemokines, pro-in fl ammatory cytokines, and the matrix-remodeling enzymes that de fi ne the SASP [49, 50].”
Signalling by senescent melanocytes hyperactivates hair growth
Wang, X., Ramos, R., Phan, A. Q., Yamaga, K., Flesher, J. L., Jiang, S., Oh, J. W., Jin, S., Jahid, S., Kuan, C., et al. (2023) · Nature · doi:10.1038/s41586-023-06172-8 · Cited by 61
Medenica, S., Abazović, D., Ljubić, A., Vuković, J., Begovic, A., Cucinella, G., Zaami, S., & Gullo, G. (2022) · International Journal of Endocrinology · doi:10.1155/2022/4842316 · Cited by 67
“Some of the molecules produced by the SASP could explain how senescent cells can alter the tissue microenvironment and draw in the immune system through autocrine and paracrine activity and, paradoxically to its biological role, cause malignant phenotypes [87, 88].”
BackgroundDark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation
Jiang, M., Gu, D.-N., Dai, J., Huang, Q., & Tian, L. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.018 · Cited by 57
Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?
Hazeldine, J., & Lord, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573662 · Cited by 67
Neri, F., Basisty, N., Desprez, P., Campisi, J., & Schilling, B. (2021) · Current Protocols · doi:10.1002/cpz1.32 · Cited by 48
“Many biological effects (both beneficial and detrimental) that senescent cells exert on organisms are triggered by their secretome, termed senescence-associated secretory phenotype (SASP; Coppe et al., 2008).”
BackgroundMethodThe BH3 Mimetic ABT-737 Induces Cancer Cell Senescence
Song, J. H., Kandasamy, K., Zemskova, M., Lin, Y.-W., & Kraft, A. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1977 · Cited by 58
“These cytokines and chemokines function to reinforce the senescent growth arrest through autocrine and paracrine mechanisms (21, 22).”
BackgroundInduction and Validation of Cellular Senescence in Primary Human Cells
Hernandez-Segura, A., Brandenburg, S., & Demaria, M. (2018) · Journal of Visualized Experiments · doi:10.3791/57782 · Cited by 53
Tamagawa, S., Sakai, D., Nojiri, H., Nakamura, Y., Warita, T., Matsushita, E., Schol, J., Soma, H., Ogasawara, S., Munesada, D., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103091 · Cited by 59
Stress‐induced responses of human skin fibroblasts in vitro reflect human longevity
Dekker, P., Maier, A. B., Van Heemst, D., De Koning‐Treurniet, C., Blom, J., Dirks, R. W., Tanke, H. J., & Westendorp, R. G. J. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00506.x · Cited by 53
“For instance, senescent cells have a secretory phenotype that promote the invasiveness of premalignant epithelial cells (Coppe et al., 2008).”
BackgroundSCAMP4 enhances the senescent cell secretome
Kim, K. M., Noh, J. H., Bodogai, M., Martindale, J. L., Pandey, P. R., Yang, X., Biragyn, A., Abdelmohsen, K., & Gorospe, M. (2018) · Genes & Development · doi:10.1101/gad.313270.118 · Cited by 53
“SASP-associated proinflammatory cytokines and growth factors were further proposed to promote tumor growth by enhancing angiogenesis and tumor cell proliferation (Krtolica et al. 2001; Liu and Hornsby 2007; Coppé et al. 2008).”
BackgroundTargeting the Tumor Stroma as a Novel Therapeutic Approach for Prostate Cancer
Franco, O. E., & Hayward, S. W. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00009-9 · Cited by 57
“These fibrocytes can be considered a progenitor cell, and depending on the stimulation they receive, can continue to replicate, become senescent, or differentiate into myofibroblasts (Coppe et al., 2008; Untergasser et al., 2005).”
BackgroundStress induced aging in mouse eye
Xu, Q., Rydz, C., Nguyen Huu, V. A., Rocha, L., Palomino La Torre, C., Lee, I., Cho, W., Jabari, M., Donello, J., Lyon, D. C., et al. (2022) · Aging Cell · doi:10.1111/acel.13737 · Cited by 53
Ribierre, T., Bacq, A., Donneger, F., Doladilhe, M., Maletic, M., Roussel, D., Roux, I. L., Chassoux, F., Devaux, B. C., Adle‐Biassette, H., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01634-2 · Cited by 63
Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo
Jackson, J. G., Post, S. M., & Lozano, G. (2011) · The Journal of Pathology · doi:10.1002/path.2783 · Cited by 53
Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyla, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K. D., Hughes, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09438-w · Cited by 52
Senescent intervertebral disc cells exhibit perturbed matrix homeostasis phenotype
Ngo, K., Patil, P., McGowan, S. J., Niedernhofer, L. J., Robbins, P. D., Kang, J., Sowa, G., & Vo, N. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.007 · Cited by 51
Zheng, K., Ma, J., Wang, Y., He, Z., & Deng, K. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201901231 · Cited by 55
Wang, Y., Liu, L., Song, Y., Yu, X., & Deng, H. (2022) · Protein & Cell · doi:10.1007/s13238-021-00894-z · Cited by 52
“1E–G, 2E and 3E), which were consistent with previous studies (Coppé et al., 2008; Purcell et al., 2014; Hernandez-Segura et al., 2018).”
InfluentialRecent progress and application of the tetrahedral framework nucleic acid materials on drug delivery
Li, J., Yan, R., Shi, S., & Lin, Y. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2276285 · Cited by 57
Cellular senescence in the tumor microenvironment and context‐specific cancer treatment strategies
Yasuda, T., Baba, H., & Ishimoto, T. (2021) · FEBS Journal · doi:10.1111/febs.16231 · Cited by 60
Subretinal injection of amyloid-β peptide accelerates RPE cell senescence and retinal degeneration
Liu, C., Cao, L., Yang, S., Xu, L., Liu, P., Wang, F., & Xu, D. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1993 · Cited by 53
“SASP proteins include a wide range of chemokines and cytokines [interleukin (IL)-6, IL-8, IL-1, granulocyte-macrophage colony-stimulating factor, monocyte chemotactic protein (MCP) and matrix metalloproteinases (MMPs)] that are known to stimulate inflammation (10,11).”
Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics
Riessland, M., & Orr, M. E. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.104 · Cited by 52
“…in the brain and myocytes of the heart; however, senescent cells infamously secrete high levels of pro-inflammatory cytokines, chemokines, and extracellular matrix-degrading proteins that negatively impact the extracellular environment and induce spread of senescence to non-senescent cells (29–32).”
BackgroundBalint, B., Yin, H. R., Nong, Z., Arpino, J., O’Neil, C. H., Rogers, S. R., Randhawa, V. K., Fox, S. A., Chevalier, J. M., Lee, J. J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.060 · Cited by 51
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.